Locally Advanced Bladder Urothelial Carcinoma

Oncology·MeSH: Carcinoma, Transitional Cell

9 drugs in development·2 companies·3 clinical trials

Drug Pipeline by Phase

Phase 3(1)

Drug	Company
Procarbazine Hydrochloride	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 2(6)

Drug	Company
Arginine hydrochloride	ENANTA PHARMACEUTICALS INC (ENTA)
Copanlisib Hydrochloride	ENANTA PHARMACEUTICALS INC (ENTA)
Defactinib Hydrochloride	ENANTA PHARMACEUTICALS INC (ENTA)
Eflornithine Hydrochloride	ENANTA PHARMACEUTICALS INC (ENTA)
Nilotinib Hydrochloride Monohydrate	ENANTA PHARMACEUTICALS INC (ENTA)
Propranolol Hydrochloride	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 4(2)

Drug	Company
Avelumab	ENANTA PHARMACEUTICALS INC (ENTA)
Enfortumab Vedotin	Fulgent Genetics Inc. (FLGT)

BioSniper tracks 9 drugs in development for Locally Advanced Bladder Urothelial Carcinoma across 2 companies.

There are 3 clinical trials targeting Locally Advanced Bladder Urothelial Carcinoma tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.